Page 287 - AIDSBK23C
P. 287

Page 287


                       In addition, screening questions applied to potential donors are aimed at determination of
               possible high-risk behaviors which exclude them as donors (sex with another man even once,
               injection drug use, etc.) and symptoms of infection (generalized lymph node enlargement,
               mucocutaneous lesions, weight loss, etc.).  Blood collection facilities also employ a confidential
               unit exclusion form which provides donors who are under duress to donate, but do not want to
               resist or answer truthfully for fear of being detected with HIV infection, to designate their blood
               as unsuitable for transfusion.  Such donor self-deferral is effective in reducing the risk of HIV
               transmission through transfusion of blood products.[1127]  Autologous donations for elective
               surgical procedures have been encouraged, but directed donations have been found to be no safer
               than the routine blood supply.[109,1128]
                       In addition to donor screening, blood processing technology can provide safeguards for
               transfusion therapy.  Whole blood fractionation can include viral reduction treatments that
               include viral inactivation steps in which mainly enveloped viruses are killed as well as viral
               removal steps where mainly non-enveloped viruses are partitioned into specific fractions.  As a
               consequence, there have been no documented transmissions since the late 1980’s of HIV,
               hepatitis B virus, and hepatitis C virus by blood products that have been subjected to such
               inactivation treatments.  This includes blood plasma and derivatives.[1129]
                       Liability problems for blood banks stem from the few blood products that have
               transmitted HIV to recipients.  In the U.S., courts in some jurisdictions have held that as long as
               blood suppliers meet professional standards of practice they are immune from liability.
               However, in other jurisdictions, blood suppliers have been found negligent despite meeting the
               established standard of care for the time period in which transmission of HIV occurred, implying
               that by maintaining liability there should be an incentive to adopt new precautionary measures to
               increase the safety level of the blood supply.  Blood banks have also been held accountable for
               maintaining confidentiality of testing donors and for maintaining records of such testing.  Many
               jurisdictions also require mandatory reporting of HIV positive donors.  Thus, potential donors
               should be advised of the confidentiality protections as well as the circumstances under which test
               results will be disclosed.[1130]
                       AIDS patients may require transfusion therapy for cytopenias resulting from progression
               of their disease and from bone marrow suppression resulting from drug therapy for infections or
               neoplasms associated with AIDS.  Additionally, zidovudine (ZDV) chemotherapy against HIV
               has as a side effect significant severe cytopenias in about 12% of patients who take this drug.
               Blood products administered to AIDS patients have the potential for graft versus host reactions,
               but there have been no significant studies to suggest that this occurs frequently.  There is no
               evidence that viral or cytokine activation occurs following blood transfusion in patients with
               advanced HIV infection, and leukoreduction appears to have no clinical benefit.[1131].
                       Transplantation of human tissues and organs also carries the potential risk for HIV
               transmission.  Transplantation involving kidney, liver, heart, pancreas, bone, and skin have been
               reported to be associated with this risk.  Nucleic acid amplification testing may reduce the risk to
               1 in 315,000 donors but a window period prior to seroconversion remains.[1132,1133]
               Autologous transplants do not carry this risk, except potentially via administrative errors.  In
               addition, HIV transmission via artificial insemination from banked sperm has occurred.  Human
               milk also carries a potential risk.[1134,1135]
                       Screening of potential donors through assessment of risk factors and through testing for
               HIV (enzyme immunoassay with Western blot confirmation) should be performed similar to that
               for blood donation.  In the case of cadaveric donors, a history must be obtained from available
   282   283   284   285   286   287   288   289   290   291   292